Table 1.

SLC26A2 overexpression is correlated with worsened disease

Tumor typeDifferential expressionFold changePDataset
BreastMetastatic event at 1 year vs. no event at 1 year2.2829.88E−10Minn Breast 2
BreastMetastatic site vs. primary site2.4850.005Weigelt Breast
BrainGlioblastoma dead at 5 years vs. alive2.5316.02E−4Nutt Brain
LungLung adenocarcioma - advanced N stage2.1250.001Beer Lung
BreastDuctal breast carcinoma- ERBB2/ER/PR negative vs. positive5.3135.75E−6Richardson Breast 2
BreastInvasive ductal breast carcinoma stroma vs. normal2.2148.23E−5Karnoub Breast
ColonColon adenocarcinoma dead at 1 year vs. alive2.6950.003TCGA Colorectal
BrainGlioblastoma vs. normal2.0026.38E−18Sun Brain
LymphomaAnaplastic large cell lymphoma vs. normal5.6412.79E−8Piccaluga Lymphoma
LymphomaAngioimmunoblastiv T-cell lymphoma vs. normal3.6895.32E−8Piccaluga Lymphoma
LymphomaUnspecified peripheral T-cell lymphoma vs. normal3.4896.22E−13Piccaluga Lymphoma
OvarianOvarian clear cell adenocarcinoma vs. normal2.3538.41E−4Lu Ovarain
ProstateProstatic intraepithelial neoplasia epithelia vs. normal3.6461.53E−4Tomlins Prostate
LiverHepatocellular carcinoma vs. normal3.2395.64E−5Wurmbach Liver
RenalNonhereditary clear cell renal carcinoma vs. normal2.3716.45E−7Beroukhim Renal
MelanomaSkin basal cell carcinoma vs. normal2.3372.15E−4Riker Melanoma
MelanomaMetastaic site vs. primary site2.0795.01E−5Xu Melanoma
RenalRenal Wilms tumor vs. normal2.2100.004Yusenko Renal
BrainGlioblastoma vs. normal2.3285.46E−5Murat Brain
BrainAnaplastic oligodendroglioma vs. normal2.3841.86E−5French Brain